The nation of Zimbabwe has declined a substantial US health deal worth 367 million US dollars (£272m) over five years over the United States' demand for sensitive information.
The decision came to light following a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa felt the deal was "unbalanced".
An official representative has since clarified that the US was seeking genetic material for scientific study and profit but was not willing to share the benefits from future medical innovations.
"We are forced to start the difficult and regrettable process of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had furnished over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for more dialogue to secure a deal acceptable to all parties so the country's critical HIV programme can proceed.
Broader Background
This development follows a comparable situation in neighbouring Kenya, where a court suspended a related deal with the US following legal challenges were raised about the security of citizens' medical information.
After returning to office recently, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump argued its spending was "wasteful" and his government was pursuing government-to-government deals to enhance transparency and accountability.
According to statements, Sixteen African countries have to date signed these new agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Agreement
The money for Zimbabwe was intended to gone towards "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration might have yielded extraordinary benefits for Zimbabwean communities, especially the 1.2 million currently on HIV treatment through US-supported initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, with no corresponding assurance of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that shared data," he stated.
"In essence, our nation would supply the basic resources for scientific discovery with no assurance that the end products would be accessible to our population should a new health crisis emerge."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the global health body and its push of one-on-one health agreements were disrupting systems previously set up via the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework created to manage potential pandemics.
"This mechanism is intended to ensure that when a nation provides its data, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the funds to develop them."
The government's concerns regarding the US deal "are not meant as opposition to America," he added.
"We encourage continued dialogue with our US partners on how subsequent co-operation might be structured in a way that respects the sovereignty and interests of each country."
Health Experts Response
Medical experts said it understood the official position, but recommended that talks should continue given that a large portion of the nation's HIV programmes were funded by external financing.
"In cases where specific concerns exist, including those relating to data governance or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," the group added.
The halted deal emphasises the continuing debate between receiving much-needed foreign assistance and safeguarding a country's data in an ever more data-driven world.